Some people are hitting a weight loss plateau with GLP-1 agonist drugs like Ozempic, so they’re turning to a stronger variety that promises even more dramatic weight loss — up to more than 70 pounds in some instances, The Atlantic reports. So the market for it is black, or at least severely grey, with shady overseas companies exploiting a legal loophole to get around regulatory barriers. “All of this stuff just scares the crap out of me,” Randy Seeley, a University of Michigan medical professor and GLP-1 agonist expert, told The Atlantic in reference to the unknown side effects of gray market drugs. This addition further revs up people’s metabolism, making them lose more weight compared to Ozempic and other GLP-1 agonist drugs. More on weight loss drugs: Low Doses of Ozempic-Like Drug Can Counteract Aging in Older Mice, Study Finds